I'd suggest it is stale AOS holders exiting Tempo, probably with more to come. I'll continue to buy because of management's track record. It will move in the right direction eventually.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor